Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation

British Journal of Surgery

Volumn 88, Issue 3, 2001, Pages 412-418

  Chan, K C ^a   Knox, W F ^a   Gandhi, A ^a   Slamon, D J ^c   Potten, C S ^b   Bundred, N J ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CARCINOMA IN SITU; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUDE MOUSE; ONCOGENE C ERB; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0035076065     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2001.01686.x     Document Type: Article

References (34)

1. Incidence of and treatment for ductal carcinoma in situ of the breast
2. Duct carcinoma in situ: Predictors of local recurrence and progression in patients treated by surgery alone
3. The pathology of ductal carcinoma in situ of the breast
4. Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast
5. Signal transduction by receptors with tyrosine kinase activity
6. The type I growth factor receptors in human breast cancer
7. Epidermal growth factor receptor, platelet-derived growth factor receptor, and c-erbB-2 receptor activation all promote growth but have distinctive effects upon mouse mammary epithelial cell differentiation
8. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner
9. Bivalence of EGF-like ligands drives the ErbB signaling network
10. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor
11. Accumulation of p21 ras. GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity
12. Involvement of G proteins, cytoplasmic calcium, phospholipases, phospholipid-derived second messengers, and protein kinases in signal transduction from mitogenic cell surface receptors
13. Mitogen regulation of c-Raf-1 protein kinase activity toward mitogen-activated protein kinase-kinase
14. Specificity of receptor tyrosine kinase signalling: Transient versus sustained extracellular signal-regulated kinase activation
15. Structure and function of human amphiregulin: A member of the epidermal growth factor family
16. PD 153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
17. Effects of tyrosine kinase inhibitor, erbstatin, on cell growth and growth-factor/receptor gene expression in human gastric carcinoma cells
18. Tyrphostin induces non-apoptotic programmed cell death in colon tumor cells
19. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists
20. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins
21. A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor
22. Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ
23. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
24. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
25. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice
26. ZD 1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition
27. EGF receptor tyrosine kinase inhibitors as anti-cancer agents - Preclinical and early clinical profile of ZD 1839
28. Pharmacokinetic/pharmacodynamic trial of ZD1839 (Iressa™), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, in patients with 5 selected tumor types (a phase I/II trial of continuous once-daily treatment)
29. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer
30. Endocrine resistance in breast cancer can involve a switch towards EGFR signalling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD 1839
31. Recent advances in chemoprevention of cancer
32. Apoptosis in cancer
33. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells
34. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling